ArticleBreast cancer research and treatment2026
Black and White disparity in U.S. female breast cancer mortality: a nationwide analysis, 1999-2023.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo comprehensively characterize the evolution of racial disparities in U.S. female breast cancer mortality between non-Hispanic Black and White women from 1999 to 2023 across age, geography, and urbanization levels.
methodsWe analyzed nationwide mortality data from the CDC WONDER database for women aged ≥ 25 years. We calculated age-adjusted mortality rates (AAMRs), absolute rate differences (ARD), and age-standardized rate ratios (ASRR). Joinpoint regression was employed to quantify temporal trends and identify significant changes over the 25-year period.
resultsBetween 1999 and 2023, AAMRs declined for both Black (Average Annual Percent Change [AAPC] = -1.38, 95% CI -1.45 - -1.30) and White (AAPC = -1.46, 95% CI -1.56 - -1.35) women; however, Black women consistently experienced higher mortality. Disparity trends exhibited significant heterogeneity. While the mortality gap narrowed for women aged ≥ 55, the relative disparity for younger women (< 55 years) remained stagnant (ASRR ~ 1.88) despite absolute rate declines. Geographically, the Midwest achieved the most significant reduction in ARD. In contrast, the Northeast showed widening relative disparities. Notably, Massachusetts experienced a "disparity reversal," shifting from a Black survival advantage in 1999 to a significant mortality disadvantage by 2023. Additionally, disparities worsened in Large Fringe Metro areas compared to other urbanization levels.
conclusionDespite national progress in reducing breast cancer mortality, racial equity remains elusive. The persistent gap among younger women and the widening disparities in specific "hotspot" regions and traditionally affluent states challenge the assumption that general healthcare improvements benefit all populations equitably, underscoring the urgent need for targeted, precision-based public health interventions.
Indexed as
Identifiers
41991749What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.